Skip to main content
Epizyme's Tazverik gains conditional approval for rare soft tissue sarcoma
1/24/2020

The FDA granted conditional approval to Epizyme's Tazverik, or tazemetostat, to treat patients with inoperable metastatic or locally advanced epithelioid sarcoma, a rare soft tissue cancer, and Epizyme announced the drug will be priced at $15,500 per month. Data from a midstage trial showed the drug shrank tumors in some patients.

Full Story: